Stuyvesant Capital Management Has Increased Pfizer (PFE) Holding by $1.42 Million; As Pacific Biosciences Calif In (PACB) Stock Value Declined, Consonance Capital Management LP Has Upped Its Position by $15.34 Million

January 13, 2018 - By olga

Stuyvesant Capital Management increased its stake in Pfizer Inc (PFE) by 41.12% based on its latest 2017Q3 regulatory filing with the SEC. Stuyvesant Capital Management bought 40,650 shares as the company’s stock declined 3.45% while stock markets rallied. The institutional investor held 139,515 shares of the health care company at the end of 2017Q3, valued at $4.98M, up from 98,865 at the end of the previous reported quarter. Stuyvesant Capital Management who had been investing in Pfizer Inc for a number of months, seems to be bullish on the $217.80 billion market cap company. The stock decreased 0.05% or $0.02 during the last trading session, reaching $36.54. About 19.20 million shares traded or 25.94% up from the average. Pfizer Inc. (NYSE:PFE) has declined 2.76% since January 13, 2017 and is downtrending. It has underperformed by 19.46% the S&P500.

Mitchell Blutt increased its stake in Pacific Biosciences Calif In (PACB) by 80.07% based on its latest 2017Q3 regulatory filing with the SEC. Consonance Capital Management Lp bought 3.07 million shares as the company’s stock declined 26.83% while stock markets rallied. The hedge fund run by Mitchell Blutt held 6.90M shares of the capital goods company at the end of 2017Q3, valued at $36.23 million, up from 3.83M at the end of the previous reported quarter. Consonance Capital Management Lp who had been investing in Pacific Biosciences Calif In for a number of months, seems to be bullish on the $316.20M market cap company. The stock increased 7.94% or $0.2 during the last trading session, reaching $2.72. About 1.52M shares traded or 56.19% up from the average. Pacific Biosciences of California, Inc. (NASDAQ:PACB) has declined 59.88% since January 13, 2017 and is downtrending. It has underperformed by 76.58% the S&P500.

Investors sentiment increased to 1.55 in Q3 2017. Its up 0.53, from 1.02 in 2017Q2. It improved, as 16 investors sold PACB shares while 17 reduced holdings. 15 funds opened positions while 36 raised stakes. 80.23 million shares or 4.63% more from 76.68 million shares in 2017Q2 were reported. Prtn Ltd has 394,800 shares. Smithfield invested in 0% or 4,862 shares. Great West Life Assurance Can stated it has 0% in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Lord Abbett And Co Ltd Liability Company reported 814,484 shares or 0.01% of all its holdings. First Mercantile Trust Co invested 0.01% of its portfolio in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Alliancebernstein Lp stated it has 103,000 shares or 0% of all its holdings. Moreover, Balyasny Asset Mngmt has 0% invested in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Natixis has 0.01% invested in Pacific Biosciences of California, Inc. (NASDAQ:PACB) for 103,662 shares. Georgia-based Invesco Limited has invested 0.01% in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Cap Investors owns 8.13M shares or 0.01% of their US portfolio. Frontier Cap Mgmt Limited Liability Com holds 0.06% of its portfolio in Pacific Biosciences of California, Inc. (NASDAQ:PACB) for 1.49 million shares. Goldman Sachs Grp has 0% invested in Pacific Biosciences of California, Inc. (NASDAQ:PACB) for 138,976 shares. Sg Americas Secs Limited holds 118,909 shares. Mutual Of America Cap Limited Liability Corporation holds 482,088 shares or 0.04% of its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) holds 2,957 shares.

Among 6 analysts covering Pacific Biosciences of California (NASDAQ:PACB), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Pacific Biosciences of California had 15 analyst reports since August 27, 2015 according to SRatingsIntel. The stock of Pacific Biosciences of California, Inc. (NASDAQ:PACB) earned “Hold” rating by First Analysis on Friday, November 3. Cantor Fitzgerald maintained the shares of PACB in report on Monday, January 4 with “Buy” rating. The stock of Pacific Biosciences of California, Inc. (NASDAQ:PACB) has “Overweight” rating given on Friday, October 23 by Piper Jaffray. The firm has “Buy” rating given on Thursday, August 27 by Maxim Group. As per Tuesday, October 10, the company rating was maintained by Piper Jaffray. C.L. King downgraded it to “Hold” rating and $6.8 target in Thursday, September 28 report. On Friday, April 15 the stock rating was initiated by M Partners with “Neutral”. The rating was initiated by CL King with “Buy” on Monday, June 27. On Thursday, February 4 the stock rating was downgraded by Piper Jaffray to “Neutral”. The rating was initiated by Cantor Fitzgerald on Thursday, August 27 with “Buy”.

Consonance Capital Management Lp, which manages about $513.80M and $904.16M US Long portfolio, decreased its stake in Amarin Corp Plc (NASDAQ:AMRN) by 175,000 shares to 24.65 million shares, valued at $86.27M in 2017Q3, according to the filing. It also reduced its holding in Advanced Accelerator Applic by 978,572 shares in the quarter, leaving it with 890,935 shares, and cut its stake in Corindus Vascular Robotics I.

Among 21 analysts covering Pfizer (NYSE:PFE), 9 have Buy rating, 1 Sell and 11 Hold. Therefore 43% are positive. Pfizer had 67 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Pfizer Inc. (NYSE:PFE) has “Hold” rating given on Thursday, October 13 by Jefferies. Argus Research downgraded Pfizer Inc. (NYSE:PFE) on Wednesday, November 2 to “Hold” rating. The firm has “Outperform” rating by Credit Suisse given on Monday, May 9. Berenberg initiated Pfizer Inc. (NYSE:PFE) rating on Thursday, May 12. Berenberg has “Hold” rating and $38 target. Citigroup downgraded the shares of PFE in report on Tuesday, May 16 to “Sell” rating. UBS maintained it with “Buy” rating and $38.0 target in Wednesday, November 1 report. Jefferies maintained the shares of PFE in report on Wednesday, August 16 with “Hold” rating. The rating was maintained by Argus Research on Wednesday, July 29 with “Buy”. Jefferies maintained the shares of PFE in report on Monday, June 20 with “Buy” rating. Jefferies maintained it with “Buy” rating and $40 target in Thursday, August 4 report.

Investors sentiment increased to 0.96 in 2017 Q3. Its up 0.02, from 0.94 in 2017Q2. It is positive, as 53 investors sold PFE shares while 700 reduced holdings. 106 funds opened positions while 620 raised stakes. 4.06 billion shares or 0.86% more from 4.02 billion shares in 2017Q2 were reported. Philadelphia Tru, Pennsylvania-based fund reported 51,078 shares. North Star Mgmt Corporation stated it has 146,209 shares. Janney Montgomery Scott Limited Liability accumulated 0.75% or 1.85 million shares. The Texas-based Frontier Investment Management Co has invested 0.1% in Pfizer Inc. (NYSE:PFE). Wafra Inv Advisory Grp Inc holds 0.09% or 51,051 shares in its portfolio. Tdam Usa accumulated 278,582 shares. Calamos Wealth Management Limited invested in 0.57% or 114,409 shares. Profund Limited invested in 0.58% or 389,807 shares. Cutler Investment Counsel Limited Liability Com reported 0.06% in Pfizer Inc. (NYSE:PFE). American Asset Inc reported 25,244 shares stake. Manning & Napier Advisors Limited Company owns 838,007 shares. Sit Inv Associate Incorporated reported 886,075 shares stake. Baker Avenue Asset Mngmt Ltd Partnership reported 0.82% of its portfolio in Pfizer Inc. (NYSE:PFE). Tru Department Mb Bancorporation N A holds 0.09% of its portfolio in Pfizer Inc. (NYSE:PFE) for 23,574 shares. Pinnacle Fincl Ptnrs owns 132,419 shares or 0.61% of their US portfolio.

Since August 4, 2017, it had 0 buys, and 10 selling transactions for $16.36 million activity. Another trade for 94,409 shares valued at $3.21M was sold by DAMELIO FRANK A. $3.30 million worth of Pfizer Inc. (NYSE:PFE) shares were sold by READ IAN C. The insider OLSON LAURIE J sold 8,064 shares worth $263,693. 38,230 shares were sold by SUSMAN SALLY, worth $1.34 million. $296,560 worth of Pfizer Inc. (NYSE:PFE) was sold by JOHNSON RADY A.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>